Sold as Bevyxxa. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Betrixaban (sold as Bevyxxa), first approved Jun 23, 2017, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)Venous Thromboembolism · Brigham and Women's Hospital | Not applicable | Recruiting | Nov 1, 2018 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 23, 2017 | BevyxxaNDA 208383 · New molecular entity | Portola Pharms Inc | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
